Kanvas Biosciences: Series ADevelops microbiome-based live biotherapeutics for cancer patients who do not respond to immunotherapyOct 4, 2026RoundOSKanvas BiosciencesCompany profile and funding historySourcesbusinesswire.comMore in BiotechAusperBio · Series CProFound Therapeutics · StrategicTransfyr · SeedAISeries A · AIBiotechUnited StatesEnterprise softwareHealthtechNorth AmericaSeries A